N/A N=84 Conservative Versus Surgical Treatment of Umbilical Pilonidal Disease
Pilonidal Sinus · Sinus; Dermal, Pilonidal · Umbilical Granuloma
Primary: Cure Rate — 28; 40 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=278 Surgical Approach for Pilonidal Disease
Pilonidal Disease
Primary: Mobilization Time,Days — 3.21; 12.3 days
N/A N=13 Pilot Study of Laser Hair Depilation for Pilonidal Disease
Pilonidal Disease
Primary: Tolerability of Laser Treatment — 2 score on a scale
Phase 4 N=100 Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst
Pilonidal Cysts
Primary: Healing Time — 78; 61 Days — p=0.094
N/A N=70 Limberg-flap: Prospective Data Collection
Pilonidal Sinus
Primary: Recurrence of a Pilonidal Sinus After Operation Using a Limberg-flap Procedure — 1 participants
N/A N=80 Video-assisted Anal Fistula Treatment Versus Seton in the Management of High Peri Anal Fistula
Post Operative Pain · Recurrence
Primary: Number of Participants With Recurrence of Disease or Fistula — 5; 10 Participants
N/A N=15 Hidradenitis Suppurativa (HS) Tunneling Wounds
Hidradenitis Suppurativa
Primary: Change in Microbiome — 5.46; 3.88 colony forming units per ml (CFU/ml)
N/A N=3,032 Perianal Fistula (PAF) Validation and Burden of Illness Study
Inflammatory Bowel Disease · Perianal Fistula · Crohns Disease
Primary: Objective 1: Number of CD Participants Who Have CPAF Using Various Codes in an TOH Database — 120; 120; 127; 127 Participants
N/A N=74 Wet-to-dry vs Petrolatum & Non-stick Dressings After Hidradenitis Suppurativa Surgery
Hidradenitis Suppurativa · Surgical Wound
Primary: Wound QOL Survey Score Over Time — 1.14; 0.94; 0.77; 0.66 score on a scale
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
N/A N=300 War-Drill Model Guided Treatment of Hemorrhoids With Nimsai Herbal (NAJ)
Hemorrhoids · Hemorrhoidal Disease
Primary: Hemorrhoid Regression Rate — 117; 33 Participants — p=<0.001
Phase 2 N=21 Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: HS Physician Local Improvement Assessment - PAIN — 7; 7; 2 Participants
N/A N=298 Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery
Surgical Site Infection
Primary: Occurrence of Superficial Surgical Site Infection — 11; 21; 107; 128 Participants
Phase 4 N=40 Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts
Epidermal Cyst
Primary: Number of Participants With Cyst Recurrence — 3; 2 participants
N/A N=100 Management of Coccydynia: A Prospective, Observational Study of Coccygectomy
Coccygodynia
Primary: Pain Change From Baseline at 2 Years — 59.08; 19.35; 20.28 units on a scale
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
N/A N=63 Idiopathic Hypertensive Anal Canal: a Place of Internal Sphincterotomy
Hypertensive Anal Canal
Primary: Effect of Closed Lateral Sphincterotomy and Chemical Sphincterotomy on Hypertensive Anal Canal
N/A N=9 Repair of Infective Wound Associated With Nerve Defect in the Finger Using A Bipedicled Nerve Flap
Infection Wound · Disruption of Nerve Repair
Primary: 2-point Discrimination Test — 7.5 mm
N/A N=120 Sacral Nerve Stimulation Therapy for the Treatment of Chronic Fecal Incontinence
Fecal Incontinence
Primary: Proportion of Subjects With at Least 50% Reduction in Number of Incontinent Episodes Per Week — 0.73 proportion of subjects — p=<0.0001
Phase 2 N=68 A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
Hidradenitis Suppurativa (HS)
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 23.8; 38.3 percentage of participants — p=0.018
N/A N=124 Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections
Surgical Site Infection · Pancreatic Neoplasms · Pancreatic Cancer
Primary: Rate of Surgical Site Infection — 6; 19 Participants — p=0.003
Phase 2 N=5 Hidradenitis Suppurativa Wound Care
Hidradenitis Suppurativa (HS)
Primary: Percent Change in Wound Size — 57.2 percentage change in wound size
N/A N=120 Prophylactic Incisional Care in Obese Women at Cesarean
Wound Infections
Primary: Number of Participants With Composite Surgical Site Infection (SSI) or Other Wound Complication. — 5; 3 Participants — p=0.72
N/A N=2 Pilot Study Evaluating the Safety and Efficacy of a Patient-Specific Enteroatmospheric Fistula Isolation and Management Device Independent of Negative Pressure Wound Therapy
Fistula · Abdominal Injury · Negative Pressure Wound Therapy
Primary: Change in Inpatient Participant Pain Rating
Phase 2 N=15 Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients
Diabetes · Infection
Primary: Efficacy of Timentin Delivered by PILP Procedure (Treatment Group) Versus Intravenous Delivery (Control Group) at Reducing Microbiological Load in Subjects With…
Phase 3 N=23 Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Abscess
Primary: Number of Participants With Abscess Resolution — 11; 9 Participants
Phase 3 N=568 Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
Crohn's Disease
Primary: Percentage of Participants With Combined Remission at Week 24 — 46.32; 48.76 percentage of participants — p==0.571
N/A N=9 Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap
Painful Digital Neuroma
Primary: Static 2-point Discrimination Test — 7.3 mm
Phase 2 N=90 A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 26.1; 59.5; 57.3 Percentage of…
N/A N=16 HidraWear Study for Hidradenitis Suppurativa Wounds
Hidradenitis Suppurativa · Hidradenitis
Primary: Ease of Use Day 21 vs Day 0 — 6.47; 0.6 score on a scale